See more : Imagination Technologies (IGZ) Income Statement Analysis – Financial Results
Complete financial analysis of INBIOGEN Co., Ltd. (101140.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of INBIOGEN Co., Ltd., a leading company in the Apparel – Footwear & Accessories industry within the Consumer Cyclical sector.
- Liminal BioSciences Inc. (LMNL) Income Statement Analysis – Financial Results
- ANG Lifesciences India Limited (ANG.BO) Income Statement Analysis – Financial Results
- Anthera Pharmaceuticals, Inc. (ANTH) Income Statement Analysis – Financial Results
- Estore Corporation (4304.T) Income Statement Analysis – Financial Results
- Relativity Acquisition Corp. (RACYW) Income Statement Analysis – Financial Results
INBIOGEN Co., Ltd. (101140.KS)
Industry: Apparel - Footwear & Accessories
Sector: Consumer Cyclical
Website: https://www.inbiogen.co.kr
About INBIOGEN Co., Ltd.
INBIOGEN CO.Ltd manufactures and sells footwear for children, youth, and adults in South Korea and internationally. The company markets its products under the ARTIS, SPECS, WANGJA, NEOSPEC, and CHAMPION brands. The company was formerly known as BTONE CO.,Ltd. INBIOGEN CO.Ltd was founded in 1949 and is based in Pyeongtaek, South Korea.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 6.24B | 11.40B | 10.48B | 10.22B | 9.80B | 7.57B | 7.08B | 11.55B | 8.86B | 11.76B | 7.97B | 10.17B | 11.95B | 14.65B | 20.39B | 20.71B |
Cost of Revenue | 4.96B | 8.84B | 8.52B | 9.41B | 8.72B | 6.76B | 6.58B | 9.92B | 9.22B | 10.04B | 6.40B | 7.85B | 8.21B | 10.99B | 14.83B | 15.85B |
Gross Profit | 1.28B | 2.56B | 1.96B | 812.06M | 1.07B | 807.54M | 494.87M | 1.63B | -354.86M | 1.73B | 1.57B | 2.32B | 3.74B | 3.66B | 5.55B | 4.86B |
Gross Profit Ratio | 20.45% | 22.47% | 18.69% | 7.95% | 10.94% | 10.67% | 6.99% | 14.11% | -4.00% | 14.68% | 19.69% | 22.82% | 31.28% | 24.99% | 27.23% | 23.47% |
Research & Development | 8.19M | 3.67M | 24.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.54M | 8.75M | 12.78M | 29.81M | 132.65M | 98.56M | 130.66M |
General & Administrative | 1.28B | 1.86B | 1.10B | 411.62M | 229.70M | 65.03M | 50.02M | 50.11M | 101.43M | 131.57M | 189.28M | 166.24M | 215.56M | 430.98M | 636.85M | 598.53M |
Selling & Marketing | 1.64B | 2.31B | 3.59B | 2.79B | 1.30B | 678.78M | 822.50M | 1.47B | 584.67M | 1.23B | 957.55M | 1.34B | 1.02B | 1.42B | 4.58B | 4.32B |
SG&A | 2.92B | 4.16B | 4.69B | 3.20B | 1.53B | 743.82M | 872.52M | 1.52B | 686.10M | 1.36B | 1.15B | 1.51B | 1.23B | 1.85B | 5.21B | 4.91B |
Other Expenses | 4.55B | 4.33B | 4.93B | 3.02B | 1.66B | -1.30B | 1.15B | 2.24B | 3.91B | 1.62B | 1.70B | 2.01B | 1.46B | 3.70B | 3.99B | 3.32B |
Operating Expenses | 7.48B | 8.50B | 9.64B | 6.22B | 3.20B | -559.64M | 2.03B | 3.76B | 4.59B | 3.00B | 2.85B | 3.53B | 2.73B | 5.69B | 9.30B | 8.37B |
Cost & Expenses | 12.45B | 17.34B | 18.17B | 15.63B | 11.92B | 6.20B | 8.61B | 13.68B | 13.81B | 13.04B | 9.25B | 11.38B | 10.94B | 16.67B | 24.13B | 24.21B |
Interest Income | 1.03B | 1.83B | 1.84B | 1.00B | 896.31M | 40.97M | 31.89M | 437.00K | 6.46M | 6.18M | 77.29M | 13.24M | 2.15M | 18.54M | 837.00K | 369.10M |
Interest Expense | 0.00 | 3.69B | 3.83B | 6.23B | 4.26B | 250.00 | 57.58M | 127.43M | 90.26M | 264.96M | 179.74M | 106.55M | 218.72M | 110.20M | 27.92M | 0.00 |
Depreciation & Amortization | 1.22B | 1.44B | 3.84B | -19.46B | 1.39B | 34.57M | 48.74M | 51.57M | 51.59M | 40.39M | 45.51M | 58.06M | 58.02M | 59.96M | 65.83M | 50.07M |
EBITDA | -4.99B | 45.46B | -7.03B | -24.87B | -1.41B | 1.40B | -1.48B | -2.08B | -5.54B | -1.31B | -1.16B | -1.20B | 1.07B | -13.72B | 2.11B | -3.46B |
EBITDA Ratio | -80.04% | 398.64% | -36.69% | -243.44% | -7.47% | 19.98% | -15.61% | -17.99% | -62.54% | -11.11% | -14.50% | -11.84% | 8.97% | -93.65% | 10.34% | -123.93% |
Operating Income | -6.21B | 44.02B | -7.69B | -5.41B | -2.13B | 1.37B | -1.53B | -2.13B | -4.95B | -1.28B | -1.28B | -1.21B | 1.01B | -2.02B | -3.75B | -3.51B |
Operating Income Ratio | -99.46% | 386.03% | -73.33% | -52.95% | -21.71% | 18.07% | -21.64% | -18.47% | -55.81% | -10.85% | -16.12% | -11.94% | 8.46% | -13.82% | -18.39% | -16.94% |
Total Other Income/Expenses | 25.58B | -130.60B | 119.00B | -39.96B | 15.25B | 1.53B | 320.53M | -124.04M | -738.75M | -336.41M | -95.95M | -155.12M | -216.25M | -11.86B | 5.76B | -22.20B |
Income Before Tax | 19.37B | -136.64B | 111.06B | -45.22B | 13.12B | 1.48B | -1.21B | -2.26B | -5.69B | -1.61B | -1.38B | -1.37B | 794.54M | -13.89B | 2.01B | -25.71B |
Income Before Tax Ratio | 310.40% | -1,198.21% | 1,059.69% | -442.55% | 133.98% | 19.52% | -17.11% | -19.54% | -64.14% | -13.71% | -17.33% | -13.46% | 6.65% | -94.81% | 9.88% | -124.17% |
Income Tax Expense | 0.00 | -16.95B | 16.94B | -140.81M | -14.11B | -187.00M | 378.12M | 3.39M | -648.49M | -71.45M | 83.78M | -48.57M | 2.47M | -11.75B | 5.79B | -22.20B |
Net Income | 18.86B | -119.69B | 94.12B | -45.08B | 27.23B | 1.66B | -1.21B | -2.26B | -5.69B | -1.61B | -1.38B | -1.37B | 794.54M | -13.89B | 2.01B | -25.71B |
Net Income Ratio | 302.16% | -1,049.54% | 898.07% | -441.17% | 278.04% | 21.99% | -17.11% | -19.54% | -64.14% | -13.71% | -17.33% | -13.46% | 6.65% | -94.81% | 9.88% | -124.17% |
EPS | 1.89K | -33.01K | 1.75K | -21.81K | 12.33K | 1.46K | -54.59 | -112.66 | -307.01 | -141.17 | -122.99 | -121.97 | 41.77 | -341.00 | 46.00 | -797.00 |
EPS Diluted | 1.89K | -33.01K | 1.58K | -21.81K | 12.33K | 1.45K | -54.59 | -112.66 | -307.01 | -141.17 | -122.99 | -121.97 | 37.79 | -341.00 | 46.00 | -797.00 |
Weighted Avg Shares Out | 9.99M | 3.63M | 2.97M | 2.07M | 2.21M | 1.14M | 1.10M | 1.00M | 926.06K | 570.95K | 561.13K | 561.13K | 951.15K | 2.04M | 2.19M | 1.61M |
Weighted Avg Shares Out (Dil) | 9.99M | 3.63M | 2.97M | 2.07M | 2.21M | 1.15M | 1.11M | 1.00M | 926.06K | 571.08K | 561.13K | 561.13K | 1.05M | 2.04M | 2.19M | 1.61M |
Source: https://incomestatements.info
Category: Stock Reports